SCHEMBL13360484

SCHEMBL13360484

Cc1c(C(C)C)sc2c1CCCCC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.35
HSD17B10 Q99714 5/20 0.35
ALDH1A1 P00352 6/20 0.34
MAPT P10636 5/20 0.34
GAA P10253 4/20 0.34
MAPK1 P28482 3/20 0.34
BPTF Q12830 1/20 0.34
KDM4E B2RXH2 4/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
APP P05067 1/20 0.33
CYP1A2 P05177 1/20 0.33
HIF1A Q16665 1/20 0.33
HTT P42858 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13360470 0.98 HSD17B10 (0.36) ALOX15HSD17B10ALDH1A1MAPTGAA
SCHEMBL19359600 0.94 ALDH1A1 (0.33) ALOX15HSD17B10ALDH1A1MAPTKDM4E
SCHEMBL13328153 0.80 ALOX15 (0.35) ALOX15HSD17B10ALDH1A1MAPTGAA
SCHEMBL13030214 0.78 HSD17B10 (0.36) ALOX15HSD17B10ALDH1A1MAPTGAA
SCHEMBL13241577 0.77 PNMT (0.33)
SCHEMBL13169597 0.76 ALDH1A1 (0.39) ALOX15HSD17B10ALDH1A1MAPTGAA
SCHEMBL10078177 0.76 ALDH1A1 (0.39) ALOX15HSD17B10ALDH1A1MAPTGAA
SCHEMBL10239408 0.76 RAB9A (0.35) ALOX15HSD17B10ALDH1A1MAPTGAA
SCHEMBL23710953 0.75 LIMK1 (0.32)
SCHEMBL13328146 0.73 ALOX15 (0.33) ALOX15HSD17B10ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718648-B2 Pyridobenzazepine compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-05-18 US disclosed
US-7572784-B2 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-11 US disclosed
US-20080045501-A1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-21 US disclosed
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185087-A1 Compounds and methods for inhibiting mitotic progression AURKC, AURKA, AURKB ALOX15 4543/4885HSD17B10 2449/4885ALDH1A1 3815/4885
US-20080045501-A1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression AURKB, AURKC, AURKA ALOX15 4476/4885HSD17B10 2094/4885ALDH1A1 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.